AI Article Synopsis

  • Many neonates with hypoxic ischemic encephalopathy and seizures do not respond to phenobarbital, which is the first-line antiepileptic drug, and there's limited knowledge about the reasons for this failure.
  • A study reviewed 50 term neonates who received phenobarbital, classifying them as responders or nonresponders based on seizure activity, MRI scans, and EEG background, revealing that nonresponders had worse scores on these metrics.
  • The findings suggest that if certain factors are present, such as high seizure scores and severe MRI injury, additional antiepileptic medications may be necessary, calling for more extensive studies to explore alternative first-line treatments for severely injured patients.

Article Abstract

Background: Many neonates with hypoxic ischemic encephalopathy and seizures do not respond to the first line antiepileptic drug, phenobarbital. Little is known about what factors are associated with its failure.

Objective: To examine factors associated with failure of phenobarbital therapy in neonates with hypoxic ischemic encephalopathy and seizures.

Design/methods: A single-center retrospective review of 50 term (>35 weeks) neonates with hypoxic ischemic encephalopathy and seizures treated with phenobarbital as the first-line antiepileptic. Neonates were classified into either responders (n = 30) or nonresponders (n = 20). Nonresponse was defined as continued seizures after maximum dosing of phenobarbital or an additional antiepileptic. Subjects with acceptable magnetic resonance imaging (MRI) scans obtained within 2 weeks of birth were included in the study and rated using an MRI injury scoring system. Charts were reviewed for demographic, clinical, and laboratory variables. Resuscitation and seizure scores were also calculated. Electroencephalographic (EEG) background activity was reviewed in 2 different time epochs (12-24 hours and 24-36 hours of life) and graded as per ACNS guidelines.

Results: There were no significant group differences in demographic, clinical, and laboratory variables except nonresponders, who had higher mean seizure score ( = .01) and significantly more injury on MRI scan for white matter ( = .004), parenchymal cortex ( = .027), and watershed ( = .009) regions. Neonates with moderately abnormal or severely abnormal background EEG responded poorly to phenobarbital.

Conclusion: In the presence of above factors, one can anticipate that additional antiepileptic medication may be needed. These data also support that larger studies should be done to look prospectively at using alternative agents first line in patients with severe injury.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0883073819838171DOI Listing

Publication Analysis

Top Keywords

hypoxic ischemic
16
ischemic encephalopathy
16
encephalopathy seizures
12
neonates hypoxic
12
factors associated
8
additional antiepileptic
8
demographic clinical
8
clinical laboratory
8
laboratory variables
8
phenobarbital
5

Similar Publications

Objectives: To build an early, prognostic model for adverse outcome in infants with hypoxic ischemic encephalopathy (HIE) receiving therapeutic hypothermia (TH) based on brain magnetic resonance images (MRI), electrophysiological tests and clinical assessments were performed during the first 5 days of life.

Methods: Retrospective study of 182 neonates with HIE and managed with TH. The predominant pattern of HIE brain injury on MRI performed following cooling was scored by neuroradiologists.

View Article and Find Full Text PDF

Analytical Validation of MSD S‐PLEX Neurology Panel 1.

Alzheimers Dement

December 2024

Meso Scale Diagnostics, LLC., Rockville, MD, USA

Background: Three blood‐based biomarkers of neurological injury—glial fibrillary acidic protein (GFAP), neurofilament light (Nf‐L), and Tau—have emerged as promising biomarkers of neurological disorders and injuries such as hypoxic‐ischemic encephalopathy (HIE), traumatic brain injury, and Alzheimer’s disease (AD). The low levels of GFAP, Nf‐L, and Tau in serum and plasma require highly sensitive assays to detect them. Here, we report the analytical validation of an ultrasensitive, electrochemiluminescence‐based, multiplexed immunoassay for neurological biomarker assessment.

View Article and Find Full Text PDF

Background: NA‐831 is a candidate for the treatment of Alzheimer’s Disease (AD). NA‐911 is an analog of NA‐831, serving as an IGF‐1 and GLP‐1 agonists. Animal studies of NA‐911 are evaluated for the treatment of by hypoxic‐ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders

Method: For NA‐831: A randomized clinical trial of NA‐831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.

View Article and Find Full Text PDF

Background: Hyperbaric oxygen therapy (HBOT) is a treatment in which oxygen‐enriched air (up to 100%) is administered to patients in a chamber at a pressure above one atmosphere absolute and is approved for the treatment of T2D ischemic wounds. Type 2 diabetes (T2D) is a risk factor for dementia. Ischemia due to vascular pathology is hypothesized to be an underlying mechanism for this association.

View Article and Find Full Text PDF

Neonatal encephalopathy (NE) presents as reduced consciousness, often with seizures, abnormal tone, feeding and respiratory difficulties. The most common cause is secondary to a hypoxic-ischaemic event. However, there are many important diagnoses that can also present as NE, so-called 'hypoxic ischaemic encephalopathy (HIE) mimics'.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!